| 摘要 |
A novel method is disclosed for selecting antibody reagents for vaccine formulations that are capable of inducing group-neutralizing anti-HIV antibody responses in humans. Also disclosed are anti-idiotype antibodies and hybridoma cell lines capable of producing such antibodies. Further, anti-idiotype antibody-based vaccines and formulations thereof are disclosed. The methods, antibodies, hybridomas and vaccine formulations of the present invention may be useful in the treatment and prevention of HIV infection. |
